NIH Funding Announcements

Syndicate content
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 48 min 14 sec ago

Education and Health: New Frontiers (R03) - Clinical Trial Optional

Wed, 11/22/2017 - 11:25
Funding Opportunity PAR-18-388 from the NIH Guide for Grants and Contracts. The goal of this funding opportunity announcement is to support research that will further elucidate the pathways involved in the relationship between education and health outcomes and in doing so to carefully identify the specific aspects and qualities of education that are responsible for this relationship and what the mediating factors are that affect the nature of the causal relationship.
Categories: NIH-Funding

Education and Health: New Frontiers (R21)- Clinical Trial Optional

Wed, 11/22/2017 - 11:25
Funding Opportunity PAR-18-362 from the NIH Guide for Grants and Contracts. The goal of this funding opportunity announcement is to support research that will further elucidate the pathways involved in the relationship between education and health outcomes and in doing so to carefully identify the specific aspects and qualities of education that are responsible for this relationship and what the mediating factors are that affect the nature of the causal relationship.
Categories: NIH-Funding

Population Health Interventions: Integrating Individual and Group Level Evidence (R01) - Clinical Trial Optional

Wed, 11/22/2017 - 10:09
Funding Opportunity PA-18-385 from the NIH Guide for Grants and Contracts. To improve health and reduce the burden of disease, scientific research needs to be implemented at the population level in addition to the biological and clinical levels. The purpose of this funding opportunity announcement (FOA) is to support multilevel, transdisciplinary population health interventions that target underlying social, economic, and environmental conditions in an effort to improve health outcomes.
Categories: NIH-Funding

Population Health Interventions: Integrating Individual and Group Level Evidence (R21) - Clinical Trials Optional

Wed, 11/22/2017 - 10:09
Funding Opportunity PA-18-407 from the NIH Guide for Grants and Contracts. To improve health and reduce the burden of disease, scientific research needs to be implemented at the population level in addition to the biological and clinical levels. The purpose of this funding opportunity announcement (FOA) is to support multilevel, transdisciplinary population health interventions that target underlying social, economic, and environmental conditions in an effort to improve health outcomes
Categories: NIH-Funding

Healthy Habits: Timing for Developing Sustainable Healthy Behaviors in Children and Adolescents (R21 Clinical Trial Optional)

Wed, 11/22/2017 - 10:07
Funding Opportunity PA-18-354 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA), issued by the National Institute of Nursing Research (NINR), is to encourage Exploratory/Developmental Research Grant (R21) applications that employ innovative research to identify mechanisms of influence and/or promote positive sustainable health behavior(s) in children and youth (birth to age 18). Positive health behaviors may include: developing healthy sleep patterns, developing effective self-regulation strategies, adaptive decision-making in risk situations, practicing proper dental hygiene, eating a balanced and nutritious diet, engaging in age-appropriate physical activity and/or participating in healthy relationships. Applications to promote positive health behavior(s) should target social and cultural contexts, including, but not limited to: schools, families, communities, population, food industry, age-appropriate learning tools and games, social media, social networking, technology and mass media. Topics to be addressed in this announcement include: effective, sustainable processes for influencing young people to make healthy behavior choices; identification of the appropriate stage of influence for learning sustainable lifelong health behaviors; the role of technology and new media in promoting healthy behavior; identification of factors that support healthy behavior development in vulnerable populations; and, identification of mechanisms and mediators that are common to the development of a range of habitual health behaviors. Given the many factors involved in developing sustainable health behaviors, applications from multidisciplinary team that include nurse scientists are strongly encouraged. The goal of this FOA is to promote research that identifies and enhances processes that promote sustainable positive behavior or changes social and cultural norms that influence health and future health behaviors.
Categories: NIH-Funding

Healthy Habits: Timing for Developing Sustainable Healthy Behaviors in Children and Adolescents (R01 Clinical Trial Optional)

Wed, 11/22/2017 - 10:07
Funding Opportunity PA-18-355 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA), issued by the National Institute of Nursing Research (NINR), is intended to encourage Research Project Grant (R01) applications that employ innovative research to identify mechanisms of influence and/or promote positive sustainable health behavior(s) in children and youth (birth to age 18). Positive health behaviors may include: developing healthy sleep patterns, developing effective self-regulation strategies, adaptive decision-making in risk situations, practicing proper dental hygiene, eating a balanced and nutritious diet, engaging in age-appropriate physical activity and/or participating in healthy relationships. Applications to promote positive health behavior(s) should target social and cultural contexts, including, but not limited to: schools, families, communities, population, food industry, age-appropriate learning tools and games, social media, social networking, technology and mass media. Topics to be addressed in this announcement include: effective, sustainable processes for influencing young people to make healthy behavior choices; identification of the appropriate stage of influence for learning sustainable lifelong health behaviors; the role of technology and new media in promoting healthy behavior; identification of factors that support healthy behavior development in vulnerable populations; and, identification of mechanisms and mediators that are common to the development of a range of habitual health behaviors. Given the many factors involved in developing sustainable health behaviors, applications from multidisciplinary team that include nurse scientists are strongly encouraged. The goal of this FOA is to promote research that identifies and enhances processes that promote sustainable positive behavior or changes social and cultural norms that influence health and future health behaviors.
Categories: NIH-Funding

Notice of Change in PA-17-299 "Small Grants for Secondary Analyses of Existing Data Sets and Stored Biospecimens (R03)"

Wed, 11/22/2017 - 08:47
Notice NOT-HD-17-027 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Mentored Clinical Scientist Research Career Development Award (Parent K08 - Independent Clinical Trial Required)

Tue, 11/21/2017 - 13:20
Funding Opportunity PA-18-372 from the NIH Guide for Grants and Contracts. The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research.
Categories: NIH-Funding

Mentored Clinical Scientist Research Career Development Award (Parent K08 - No Independent Clinical Trials)

Tue, 11/21/2017 - 13:20
Funding Opportunity PA-18-373 from the NIH Guide for Grants and Contracts. The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research.
Categories: NIH-Funding

Independent Scientist Award (Parent K02 - Independent Clinical Trial Required)

Tue, 11/21/2017 - 12:22
Funding Opportunity PA-18-370 from the NIH Guide for Grants and Contracts. The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate.
Categories: NIH-Funding

Independent Scientist Award (Parent K02 - Independent Clinical Trials Not Allowed)

Tue, 11/21/2017 - 12:22
Funding Opportunity PA-18-371 from the NIH Guide for Grants and Contracts. The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate.
Categories: NIH-Funding

Pilot and Feasibility Therapeutic Clinical Trials in Diabetes, and Endocrine and Metabolic Diseases (R21- Clinical Trial Required)

Tue, 11/21/2017 - 11:49
Funding Opportunity PA-18-405 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement encourages the submission of pilot and feasibility therapeutic trials conducted in humans that will lay the foundation for larger clinical trials related to the prevention and/or treatment of diabetes or selected endocrine and genetic metabolic diseases within the mission of NIDDK. The program will support short-term clinical trials in humans to acquire preliminary data and/or refine power calculations that would lead to a larger, more definitive study impacting clinical care or health outcomes. This FOA is not appropriate for mechanistic clinical trials.
Categories: NIH-Funding

Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)

Tue, 11/21/2017 - 11:26
Funding Opportunity PAR-18-268 from the NIH Guide for Grants and Contracts. The overall goal of this initiative is to identify neurophysiological measures as potential assays for treatment development research. The FOA will support efforts to optimize and evaluate measures of neurophysiological processes that are disrupted within or across mental disorders in both healthy humans and in another species relevant to the therapeutic development pipeline. The initiative will support initial proof of concept studies aimed at identifying measures for potential development as preclinical assays for evaluating potential new drug and device therapies and their targets. Data will also reveal assay measures where the performance between preclinical animal species and humans is dissimilar, thus establishing a firm basis for limiting speculative extrapolations of preclinical animal findings to humans. The ultimate practical goal of this FOA is to improve the efficiency of the therapeutic development process by identifying coherence of measures and inconsistencies between the preclinical screening pipeline and clinical evaluation of new treatment candidates and thereby hasten the development of more effective treatments for mental disorders.
Categories: NIH-Funding

IDeA Networks of Biomedical Research Excellence (INBRE) (P20 Clinical Trial Optional)

Tue, 11/21/2017 - 11:24
Funding Opportunity PAR-18-262 from the NIH Guide for Grants and Contracts. The National Institute of General Medical Sciences (NIGMS) invites applications for Institutional Development Award (IDeA) Networks of Biomedical Research Excellence (INBRE) awards from investigators at biomedical research institutions that award doctoral degrees in the health sciences or sciences related to health or at independent biomedical research institutes with ongoing biomedical research programs funded by the NIH or other Federal agencies within the IDeA eligible states. The purpose of the INBRE program is to augment and strengthen the biomedical research capacity of an IDeA-eligible state. The INBRE program represents a collaborative effort to sponsor research between research intensive institutions and institutes, primarily undergraduate institutions, community colleges, and Tribally Controlled Colleges and Universities (TCCUs), as appropriate.
Categories: NIH-Funding

Limited Competition: Exploratory CTSA Collaborative Innovation Awards (R21 Clinical Trial Optional)

Tue, 11/21/2017 - 11:18
Funding Opportunity PAR-18-245 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support highly innovative, exploratory, collaborative research projects in the NCATS Clinical and Translational Science Award (CTSA) program, with the goal of assessing utility and feasibility of proposed innovation(s).
Categories: NIH-Funding

Collaborative Innovation Award, Clinical and Translational Science Award (CTSA) Program (U01 Clinical Trial Optional)

Tue, 11/21/2017 - 11:16
Funding Opportunity PAR-18-244 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to invite applications to stimulate innovative collaborative research in the NCATS Clinical and Translational Science Award (CTSA) consortium.
Categories: NIH-Funding

National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental or Substance Use Disorders or Alcohol Addiction (U19 Clinical Trial Optional)

Tue, 11/21/2017 - 11:13
Funding Opportunity PAR-18-231 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to: accelerate innovative drug and device discovery; develop pharmacologic and neuromodulatory tools for basic and clinical research on mental disorders, substance use disorders (SUDs) or alcohol addiction; develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative new candidates for mental disorders; and support early stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)-ready agents or Pre-Market Approval (PMA)-ready devices for the treatment of mental disorders, SUDs or alcohol addiction. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders or SUDs or alcohol addiction, and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged.
Categories: NIH-Funding

Reducing the Duration of Untreated Psychosis in the United States (R01 Clinical Trial Required)

Tue, 11/21/2017 - 11:01
Funding Opportunity PAR-18-233 from the NIH Guide for Grants and Contracts. Approximately 100,000 adolescents and young adults in the United States experience a first episode of psychosis (FEP) every year. The early phase of psychotic illness is widely viewed as a critical opportunity for indicated prevention, and a chance to alter the downward trajectory and poor outcomes associated with schizophrenia and related psychotic disorders. Compared to traditional treatment approaches, programs that integrate pharmacologic, psychological, and rehabilitation interventions for FEP, i.e., team-based Coordinated Specialty Care (CSC), have been found to produce a range of positive clinical and functional outcomes. However, the timing of treatment is critical; short and long-term outcomes are better when individuals begin treatment close to the onset of psychosis. Unfortunately, numerous studies find a substantial delay between the onset of psychotic symptoms and the initiation of FEP care; in the U.S. treatment is typically delayed between one and three years. Early identification of FEP, rapid referral to evidence-based services, and effective engagement in CSC are essential to shortening the duration of untreated psychosis (DUP) and pre-empting the functional deterioration common in psychotic disorders. The World Health Organization advocates reducing DUP to 3 months or less. Accordingly, this Funding Opportunity Announcement (FOA) seeks research project grant applications that test practical, reproducible strategies for substantially reducing DUP among persons with FEP by eliminating bottlenecks or closing gaps in the pathway to CSC services.
Categories: NIH-Funding

Reducing the Duration of Untreated Psychosis in the United States (R34 Clinical Trial Required)

Tue, 11/21/2017 - 10:52
Funding Opportunity PAR-18-232 from the NIH Guide for Grants and Contracts. Approximately 100,000 adolescents and young adults in the United States experience a first episode of psychosis (FEP) every year. The early phase of psychotic illness is widely viewed as a critical opportunity for indicated prevention, and a chance to alter the downward trajectory and poor outcomes associated with schizophrenia and related psychotic disorders. Compared to traditional treatment approaches, programs that integrate pharmacologic, psychological, and rehabilitation interventions for FEP, i.e., team-based Coordinated Specialty Care (CSC), have been found to produce a range of positive clinical and functional outcomes. However, the timing of treatment is critical; short and long-term outcomes are better when individuals begin treatment close to the onset of psychosis. Unfortunately, numerous studies find a substantial delay between the onset of psychotic symptoms and the initiation of FEP care; in the U.S. treatment is typically delayed between one and three years. Early identification of FEP, rapid referral to evidence-based services, and effective engagement in CSC are essential to shortening the duration of untreated psychosis (DUP) and pre-empting the functional deterioration common in psychotic disorders. The World Health Organization advocates reducing DUP to 3 months or less. Accordingly, this Funding Opportunity Announcement (FOA) seeks planning grant applications that (1) identify a baseline rate of DUP in community settings that include CSC programs; (2) map referral pathways to CSC care, (3) identify bottlenecks and gaps in the pathway to CSC care, and (4) develop and pilot test feasible strategies for substantially reducing DUP among persons with FEP.
Categories: NIH-Funding

National Cooperative Drug/Device Discovery/Development Groups (U01 Clinical Trial Optional)

Tue, 11/21/2017 - 10:43
Funding Opportunity PAR-18-230 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to: accelerate innovative drug and device discovery; develop pharmacologic and neuromodulatory tools for basic and clinical research on mental health, substance use disorders (SUDs) or alcohol addiction; develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative new candidates for mental disorders; and support early stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)-ready agents or Pre-Market Approval (PMA)-ready devices for the treatment of mental disorders, SUDs or alcohol addiction. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders or SUDs or alcohol addiction, and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged.
Categories: NIH-Funding